Evidence map›Paper›PMID 32016633›Full record

ArticleMolecular biology reports2020

Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.

Zahra Bigdelou, Yousef Mortazavi, Zohreh Saltanatpour, Zoleykha Asadi, Mehdi Kadivar, Behrooz Johari

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zahra BigdelouDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Yousef MortazaviDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Zohreh SaltanatpourDepartment of Genetics, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research, Tehran, Iran.
Zoleykha AsadiDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Mehdi KadivarDepartment of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Behrooz JohariDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Behroozjohari@yahoo.com.ORCID http://orcid.org/0000-0003-3440-572X
Zanjan University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRPasteur Institute of Iran · IR

Funding

Zanjan University of Medical Sciences Ethical Code ZUMS.REC.1397.48Zanjan University of Medical Sciences Grant Number A-12-1244-2
6 · The paper itself

Abstract

Cancer stem cells are commonly tolerant toward chemotherapy and radiotherapy. Oct4 and Sox2 transcription factors are shown to be overexpressed in various cancers. At the current research, inhibition of Oct4 and Sox2 transcription factors was performed through application of decoy oligodeoxynucleotides (ODNs) strategy via repressing stemness properties in HT29-ShE cells encompassing enriched cancer stem-like cells. Designed Oct4-Sox2 complex decoy ODNs were transfected into HT29-ShE cells with Lipofectamine reagent. At the next step, ODNs efficiency transfection and subcellular localization were determined via flow cytometry and fluorescence microscopy, respectively. Further investigations such as cell proliferation and apoptosis analysis, colonosphere formation, invasion and migration, and real-time PCR assays were also carried out. Obtained results shed light on the fact that the designed complex decoys were effectively transfected into HT29-ShE cells, and they were found to be localized in subcellular compartments. Oct4-Sox2 decoy ODNs led to decreased cell viability, arresting the cell cycle in G0/G1 phases, increasing apoptosis, inhibition of migration/invasion and colonosphere formation ability of HT29-ShE cells in comparison with control and scramble groups. Furthermore, Oct4-Sox2 complex decoy could modulate the MET process via alteration of mRNA expression of downstream genes. It could be concluded that application of Oct4-Sox2 transcription factor decoy strategy in cells with stemness potential could lead to inhibiting the cell growth and triggering differentiation. Therefore, this technique could be applied along with usual remedies (chemotherapy and radiotherapy) as high potential method for treating cancer.

Indexed as

Cell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionFlow CytometryGene Expression Regulation, NeoplasticGene Regulatory NetworksHT29 CellsHumansMicroscopy, FluorescenceMultiprotein ComplexesNeoplastic Stem CellsOctamer Transcription Factor-3OligodeoxyribonucleotidesSOXB1 Transcription FactorsMultiprotein ComplexesOctamer Transcription Factor-3OligodeoxyribonucleotidesPOU5F1 protein, humanSOX2 protein, humanSOXB1 Transcription FactorsAntitumor effectsCancer stem-like cellDifferentiation therapyOct4Oligodeoxynucleotides decoySox2Transcription factors

Identifiers

PMID32016633
OpenAlexW3004468037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.